News|Articles|May 27, 2026

Anticipated Data and Practice-Changing Trials: An ASCO 2026 Breast Cancer Preview

Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.

The upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is poised to showcase pivotal data that could reframe treatment paradigms across the breast cancer spectrum, from early-stage de-escalation strategies to novel therapeutics for advanced disease. Ahead of the meeting, MinhTri Nguyen, MD, and Nerea Lopetegui, MD, shared their insights with CancerNetwork® on the specific clinical trials, regulatory debates, and emerging modalities generating the most significant professional anticipation.

Related to this article

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

October 9th, 2026

Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer

“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

October 9th, 2026

Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization

Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

$Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.$

October 9th, 2026

Ramantamig Achieves “Impressive” Rates of MRD Negativity in RRMM

Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

October 9th, 2026

Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

October 8th, 2026

How to Navigate Ramantamig’s Low-Grade Toxicities in Multiple Myeloma

Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.

“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.

October 8th, 2026

How Can Cooperative Groups Close Outcome Gaps in HIV-Associated Lymphoma?

“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.

October 7th, 2026

Weighing Safety vs Persistence With CAR NK Cell Therapy

Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with trade-offs in persistence and response durability.

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.

October 7th, 2026

What Does NRG GU002 Mean for Docetaxel After Prostatectomy?

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.